anti-CD33/CD3 bispecific antibody

A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD33/CD3 bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and CD33 on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.